Amarin

AMRN

Amarin Corporation is a biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid. In July 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval, competing against GlaxoSmithKline's Lovaza.

Amarin has been a target of short sellers for a while. The current short interest of 2.42% is roughly at the average of the last 12 months (2.24%).